Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341600 · ClinicalTrials.gov registry record · NA
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
A NA study of Metabolism of Clopidogrel, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01341600: Completed NA study of Metabolism of Clopidogrel, sponsored by University of Maryland, Baltimore.
NCT01341600 is a NA study of Metabolism of Clopidogrel that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01341600, a NA study of Metabolism of Clopidogrel, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug. The variation in treatment response may be linked to genetics. This study will examine the effects of clopidogrel in a population in which sequencing for certain genes has been performed in order to determine the role that genes play in the response to various clopidogrel maintenance doses.
Primary Outcome
Adenosine diphosphate (ADP) mediated platelet aggregation measured 4 hours post-dose of clopidogrel on Day 1.
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Omeprazole/Clopidogrel
Study Locations (1)
Pennsylvania
- Amish Research Clinic - Lancaster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-05 |
| Phase | NA |
What the finished NCT01341600 record still lists
NCT01341600 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Metabolism of Clopidogrel appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.
NCT01341600 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01341600 about?
NCT01341600 is a clinical study titled "Clopidogrel Pharmacogenetics (PGX) Bench to Bedside". Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug. The variation in treatment response may be linked to genetics. This study wi...
What is the current status of trial NCT01341600?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2010-07. Estimated completion is 2011-05.
What conditions does trial NCT01341600 study?
This clinical trial studies the following conditions: Metabolism of Clopidogrel.
What interventions are being tested in trial NCT01341600?
The interventions under investigation include: Clopidogrel (DRUG), Omeprazole/Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT01341600?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01341600 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01341600's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia